Mathieu Blery
14Patents
5h-index
18Co-inventors
59Inventor score
Filing activity: Oct 13, 2006 → Jun 29, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9447185B2 | Compositions and methods for treating proliferative disorders | Human Necessities | 21 | Active |
| US10329348B2 | Treatment of cancers using anti-NKG2A agents | Chemistry; Metallurgy | 15 | Active |
| US10676523B2 | Treatment regimens using anti-NKG2A antibodies | Chemistry; Metallurgy | 7 | Active |
| US10711063B2 | Neutralization of inhibitory pathways in lymphocytes | Chemistry; Metallurgy | 7 | Active |
| US10870700B2 | Neutralization of inhibitory pathways in lymphocytes | Chemistry; Metallurgy | 6 | Active |
| US10344087B2 | Treatment of peripheral T cell lymphoma | Physics | 3 | Active |
| US11225519B2 | Treatment of cancers using anti-NKG2A agents | Chemistry; Metallurgy | 3 | Active |
| US10577416B2 | Mica binding agents | Physics | 3 | Active |
| US11572410B2 | Neutralization of inhibitory pathways in lymphocytes | Chemistry; Metallurgy | 3 | Active |
| US11377492B2 | NKp46 binding agents | Chemistry; Metallurgy | 1 | Active |
| US10494433B2 | Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma | Chemistry; Metallurgy | 1 | Active |
| US12365731B2 | NKp46 binding agents | Chemistry; Metallurgy | 0 | Active |
| US11999784B2 | Treatment of peripheral T cell lymphoma | Physics | 0 | Active |
| US12037392B2 | Treatment regimens using anti-NKG2A antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.